eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
1/2019
vol. 36
 
Share:
Share:
more
 
 
abstract:
Original paper

Does omalizumab treatment affect serum dehydroepiandrosterone sulphate levels in chronic idiopathic urticaria?

Atıl Avcı, Deniz Avcı, Ragip Ertas, Mustafa Atasoy, Cigdem Karakukcu, Efşan Yontar, Yilmaz Ulas, Kemal Ozyurt

Adv Dermatol Allergol 2019; XXXVI (1): 92-97
Online publish date: 2019/02/22
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
It is known that serum dehydroepiandrosterone sulphate (DHEA-S) levels are low in patients with chronic idiopathic urticaria.

Aim
In the study, the effect of the drug on the DHEA-S serum levels and its correlation with the remission and relapse times of the disease was investigated.

Material and methods
Fifty-seven patients with chronic idiopathic urticaria who were referred to our hospital and 20 healthy volunteers were included in the study. A subcutaneous injection of 300 mg omalizumab was administered to the patient group. Drug injections at this dose were completed (6 injections in total, one per month). Relations between serum DHEA-S levels and relapse rates, treatment response and remission duration of the patients and control group were investigated in the groups. 

Results
Median DHEA-S value before treatment was 116.3 (21.5–448.7) µg/dl; the median DHEA-S value measured after 3 months was 98.4 (10.0–410.0) µg/dl (p = 0.003). The median DHEA-S value before treatment was 123.1 (21.5–299.6) µg/dl when the initial and 3-month DHEA-S levels of the 34 complete remission patients were compared; after 3 months the value was 100.4 (23.1–301.9) µg/dl (p = 0.021).

Conclusions
This is the first study to investigate the effect of omalizumab treatment on DHEA-S levels in the treatment of chronic urticaria according to our literature review. The DHEA-S levels were found to be significantly lower after omalizumab therapy but not related to remission and relapse times.

keywords:

omalizumab, chronic idiopathic urticaria, inflammation, dehydroepiandrosterone sulphate

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe